EGFR and neoplasm: Analysis of the subpopulation who received other treatments (i.e., non-TKI monotherapy, including chemotherapy alone or in combination with immunotherapy, as well as EGFR-TKI combinations) showed no significant differences between the TP53 co-mutation and TP53 wild-type groups in rwPFS (median 7.4 vs. 10.0 months, HR = 0.9, 95% CI 0.5–1.6), and OS (median 25.6 vs. 24.5 months, HR = 1.3, 95% CI 0.7–2.3), although the results are limited by the relatively small sample size (n = 89 patients, 50 with TP53 co-mutation and 39 with TP53 wild-type tumor), Supplementary Table S6.